PMS28 BUDGET IMPACT ANALYSIS OF TOFACITINIB FOR RHEUMATOID ARTHRITIS FROM THE PERSPECTIVE OF THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM
Rheumatoid arthritis (RA) is an inflammatory autoimmune and chronic disease that affects the joints of the body covered by the synovial membrane, causing significant morbidity and premature mortality.
Currently there is no cure for this condition described.
Treatment focuses on remission or achieve and maintain low disease activity and therapies are directed at the control of symptoms of pain and inflammation joints, minimizing the functional loss, maintaining the quality of life and reducing the risk of damage and disability. [1] [2] [3] Tofacitinib is an active immunosuppressant:
-oral administration (unnecessary cold chain)
-acts as a potent and selective inhibitor of Janus kinase family (JAK), more specifically JAK3 and JAK1, with an important role in cytokine signal transduction that regulates survival, proliferation, differentiation and apoptosis of lymphocytes 4 .
-adequate response in monotherapy.
-may provide multiple benefits for patients, doctors .
-short half-life.
-innovative mechanism of action is considered beneficial to patients non-responsive to current therapy DMARD. 4 Furthermore, its expected to generate cost reduction in aggregate costs due to oral administration, requiring less resources than an by infusion made with biologic products, and does not require transportation and cold chain storage.
Therefore, could be the expectancy of budgetary impact in the current Private Brazilian Perspective.
OBJECTIVE
The use of tofacitinib may decrease the total treatment costs in the Brazilian private healthcare system for patients with moderate to severe RA.
INTRODUCTION
To assess the budget impact of tofacitinib standardization in Brazilian private healthcare system for the treatment of moderate to severe Rheumatoid Arthritis (RA).
The total cost of tofacitinib treatment (BRL 3, 510.46) is lower than the mean total cost of treatment with biological 
